AbstractIntroduction: Dysfunctional Uterine Bleeding is the most common cause of abnormal vaginal bleeding during a woman’s reproductive years. ‘Ormeloxifene’ a nonsteroidal selective estrogen receptor modulator (SERM), is currently undergoing clinical evaluation for the treatment of heavy menstrual bleeding. It normalizes the bleeding from the uterine cavity by regularizing the expression of estrogen receptors on the endometrium.
Aim and Objectives: To study the efficacy of Ormeloxifene in the management of dysfunctional uterine bleeding.
Material and Methods: A total of 50 women between 20 to 50 years of age presenting with abnormal or dysfunctional uterine bleeding during a period of one year included in the study. During each visit a detailed menstrual history was taken and PBAC score was calculated. All patients of DUB under study treated with Ormeloxifene and the treatment outcome measured.
Results: Among a total of 50 patients, there were 25 (50%) patients belonged to 31-40 years age group with 37.9 years to be a mean of all ages. The mean Hb level recorded was 7.3gm%. The mean PBAC score prior to treatment was 274 which was found to be decreased upto 91.7 after a treatment of 3 months with Ormeloxifene.
Conclusions: DUB is considered to be caused because of the hormonal imbalance, eventually leading to hyperestrogenic state, which can be quite successfully treated by the medical management, like Ormeloxifene.
Keywords: Dysfunctional Uterine Bleeding.